Noah Rosenberg takes chief medical officer role at Esperion
Will develop and manage the firm’s clinical programmes
Over the past decade, Dr Rosenberg has held senior posts in the pharmaceutical industry, including leadership roles in medical affairs, clinical development and administration in the US and globally at Pfizer, Sanofi and Forest Labs. He has experience working on compounds in all phases of drug development including late stage drugs such as Lipitor and Lantus. Most recently at Forest Research Institute, he led the in-licensing of the GK1-399 programme.
‘Esperion has an established reputation for productivity and success and I look forward to moving novel therapies such as ETC-1002 further along in clinical development,’ Dr Rosenberg said.
You may also like
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Sustainability
PFAS regulation pressure intensifies as new Chemspec whitepaper urges early industry action
A new whitepaper launched at Chemspec Europe 2026 warns that tightening global PFAS regulation could trigger major supply chain and compliance challenges for chemical manufacturers unless companies begin transition planning now
Digital
Cytiva launches next-generation Biacore 8 SPR systems for accelerated drug discovery
The company has introduced its new Biacore 8S and 8S+ surface plasmon resonance systems, combining high-throughput screening, molecular characterisation and automated workflows to support faster and more confident drug discovery
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Drug Delivery
No more needles? How intradermal delivery could transform vaccine access
A new review has put forward novel needle-free Intradermal (ID) delivery formats as an effective alternative to traditional administration using needles, with the technologies demonstrating improved immunisation coverage and cost savings
Research & Development
Concept Life Science and OpenBench team up on AI-driven hit discovery platform for biotechs
The pair will combine AI-powered virtual screening, medicinal chemistry and in-vitro validation in a fee-for-success model designed to accelerate hit identification and reduce early-stage drug discovery risk for biotech firms
Microbiology
AMR Bio launches as clinical-phase biotech to advance Phase III-ready topical antimicrobial XF-73
The firm has announced its launch as a clinical-stage biotechnology company focused on advancing XF-73 Nasal, a first-in-class topical gel, towards Phase III development and commercialisation as a pre-surgical decolonisation treatment